These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 11165197

  • 1. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs.
    Massart C, Orgiazzi J, Maugendre D.
    Clin Chim Acta; 2001 Feb; 304(1-2):39-47. PubMed ID: 11165197
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 3. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K.
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Detection of low titre TBII in patients with Graves' disease using recombinant human TSH receptor.
    Morgenthaler NG, Nagata A, Katayama S, Bergmann A, Iitaka M.
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):193-8. PubMed ID: 12153597
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK.
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):585-90. PubMed ID: 1358483
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K.
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [Abstract] [Full Text] [Related]

  • 10. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 11. Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease.
    Ochi Y, Hamazu M, Kajita Y, Nagata A.
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):405-12. PubMed ID: 11940054
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thyroglobulin, thyrotropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves' disease within one year.
    Talbot JN, Duron F, Féron R, Aubert P, Milhaud G.
    J Endocrinol Invest; 1989 Oct; 12(9):589-95. PubMed ID: 2573625
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical validity of intercellular adhesion molecule-1 (ICAM-1) and TSH receptor antibodies in sera from patients with Graves' disease.
    Massart C, Sonnet E, Gibassier J, Maugendre D, Genetet B.
    Clin Chim Acta; 1997 Sep 30; 265(2):157-68. PubMed ID: 9385458
    [Abstract] [Full Text] [Related]

  • 16. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec 30; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 17. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K, Yamazaki K, Yamada E, Kanaji Y, Miura M, Obara T.
    Thyroid; 1999 Oct 30; 9(10):979-88. PubMed ID: 10560951
    [Abstract] [Full Text] [Related]

  • 18. Use of Chinese hamster ovary cell lines transfected with cloned human thyrotropin receptor for the measurement of thyroid-stimulating antibodies: advantages and difficulties.
    Massart C, Gibassier J, Vérité F, Fergelot P, Maugendre D.
    Clin Chim Acta; 2000 Jan 20; 291(1):67-81. PubMed ID: 10612718
    [Abstract] [Full Text] [Related]

  • 19. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P.
    Thyroid; 1998 Feb 20; 8(2):119-24. PubMed ID: 9510119
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease.
    Kasagi K, Iida Y, Hatabu H, Tokuda Y, Arai K, Endo K, Konishi J.
    Acta Endocrinol (Copenh); 1988 Feb 20; 117(2):173-80. PubMed ID: 2454576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.